A Study of LY3015014 in Participants With High Cholesterol

Status Completed

Clinical Trial Summary

This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol. The study will also investigate how the body processes the drug and how the drug affects the body. Participants will remain on a stable diet and will continue taking cholesterol-lowering medications (statins with or without ezetimibe). After signing the informed consent document, the participant will complete a screening/run-in period that will last at most 8 weeks. Then, the treatment period will last approximately 16 weeks. After the treatment period, the participants will complete a follow-up period lasting approximately 8 weeks for a total study duration ranging from approximately 25 to 32 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hypercholesterolemia

Clinical Trial Details

NCT number	NCT01890967
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 2
Start date	June 2013
Completion date	June 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04998695` - Health Effects of Consuming Olive Pomace Oil	N/A
Recruiting	`NCT03947866` - Ezetimibe-Rosuvastatin Evaluation Study
Completed	`NCT01709513` - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)	Phase 3
Completed	`NCT01212900` - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression	Phase 4
Completed	`NCT00001154` - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed	`NCT02550288` - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)	Phase 3
Completed	`NCT03929198` - Translation of Pritikin Program to the Community	N/A
Completed	`NCT04485793` - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia	N/A
Completed	`NCT02341924` - Validating the "Foods for Health" Portfolio of Functional Food Products	N/A
Active, not recruiting	`NCT02223793` - Vascular Lifestyle-Intervention and Screening in Pharmacy	N/A
Completed	`NCT01934608` - The Effect of Synching Prescription Refills on Adherence	N/A
Completed	`NCT01941836` - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients	Phase 2
Recruiting	`NCT01705873` - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen	N/A
Completed	`NCT01670734` - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects	Phase 1
Completed	`NCT01678521` - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients	N/A
Completed	`NCT01370603` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)	Phase 3
Completed	`NCT01370590` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)	Phase 3
Completed	`NCT01446679` - Special Drug Use-Results Survey of Lipitor Tablets	N/A
Completed	`NCT01575171` - Using Nudges to Implement Comparative Effectiveness	N/A
Completed	`NCT01768403` - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia	N/A